

# Hepatorenal Syndrome Global Market Report 2025: Insights into Market Drivers, Trends, Growth Predictions and Key Players

*The Business Research Company's  
Hepatorenal Syndrome Global Market  
Report 2025 - Market Size, Trends, And  
Global Forecast 2025-2034*

LONDON, GREATER LONDON, UNITED  
KINGDOM, May 14, 2025  
/EINPresswire.com/ -- The Business  
Research Company's Latest Report  
Explores Market Driver, Trends,  
Regional Insights - Market Sizing & Forecasts Through 2034

The Business  
Research Company

Hepatorenal Syndrome Market Report 2025 - Market  
Size, Trends, And Global Forecast 2025-2034

Riding on the wave of healthcare advancements and an increasing incidence of liver diseases, the hepatorenal syndrome market has witnessed marked growth in recent years. The market is

“

The Business Research  
Company's Latest Report  
Explores Market Driver,  
Trends, Regional Insights -  
Market Sizing & Forecasts  
Through 2034

”

*The Business Research  
Company*

projected to expand from \$1.29 billion in 2024 to \$1.38 billion in 2025, clocking an impressive compound annual growth rate CAGR of 7.5%. Factors propelling this growth encompass a rise in healthcare expenditure, escalating hepatitis infections, government-driven initiatives, prevalence of virally infected liver diseases, and bolstered investments in research and development.

Is the Market Set to Witness Substantial Growth?

Looking ahead, the [hepatorenal syndrome market size](#) is slated for substantial growth, projected to reach \$1.83

billion in 2029. This translates to a compound annual growth rate CAGR of 7.3%, powered by a rising prevalence of liver diseases, increase in liver transplant programs, disease prevalence, an increase in cases of direct kidney injury, and heightened incidence of liver diseases. Key trends anticipated to shape the growth trajectory during this forecast period include advanced technologies, government support programs, improved diagnostic tools, advancements in personalized medicine, and innovations in nephrology.

Get Your Free Sample Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=22001&type=smp>

What Are The Key Drivers Underpinning The [Growth Of The Hepatorenal Syndrome Market](#)?

An exponential rise in liver diseases is touted to propel the growth trajectory of the hepatorenal syndrome market. Liver diseases encompass conditions that impede liver function, such as hepatitis, cirrhosis, fatty liver, liver cancer, genetic disorders, and autoimmune diseases. A confluence of factors, including obesity, diabetes, alcohol use, viral infections, poor diet, and exposure to toxins, have contributed to the increase in liver diseases. For instance, the UK hospital admissions for liver disease reported an upward surge to 155.2 per 100,000 in 2023, up from 150.6 per 100,000 in 2022, according to the Office for Health Improvement & Disparities OHID.

A spike in research and development investments is another growth driver of the market. These investments are targeted at facilitating innovation, product improvement, and the development of new technologies. The ascension in these R&D investments propels advancements in innovative therapies, diagnostic tools, and treatment approaches for hepatorenal syndrome, thereby enhancing patient outcomes and survival rates.

Who are the [Key Players Impacting the Hepatorenal Syndrome Market](#) Landscape?

The hepatorenal syndrome market is characterized by the presence of several eminent players, including Eli Lilly and Company, Becton Dickinson and Company, Teva Pharmaceutical Industries Ltd, Baxter International Inc., Ferring Pharmaceuticals Ltd, Mallinckrodt Pharmaceuticals, Zentiva k.s, and others. These companies play a monumental role in shaping market dynamics and introducing innovative solutions for hepatorenal syndrome treatment.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/hepatorenal-syndrome-global-market-report>

What are Emerging Trends in the Hepatorenal Syndrome Market?

A prevailing trend in the hepatorenal syndrome market is the development of innovative devices, such as the cytopheretic device Cytosorb. This device is designed to reduce systemic inflammation and immune activation in critically ill patients, including those battling Hepatorenal Syndrome HRS. Recently, SeaStar Medical Holding Corporation received FDA approval in October 2023 for its Selective Cytopheretic Device SCD exclusively designed to treat hepatorenal syndrome HRS. This pathbreaking, cell-directed therapy targets hyperinflammation, a key catalyst of kidney dysfunction in patients with acute-on-chronic liver failure.

## How is the Hepatorenal Syndrome Market Segmented?

Here is a snapshot of the significant market segments –

- 1 By Type: Type 1 Hepatorenal Syndrome, Type 2 Hepatorenal Syndrome, Other Types
- 2 By Treatment: Liver Transplantation, Terlipressin Infusion, Albumin Infusion, Hemodialysis, Vasoconstrictors, Antibiotic Therapy
- 3 By Diagnosis: Complete Blood Cell Count, Liver Function Tests, Urinalysis And Urine Electrolytes, Other Diagnosis
- 4 By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels
- 5 By End Users: Hospitals, Homecare, Specialty Clinics, Other End Users

### Regional landscapes:

- 1 By Type 1 Hepatorenal Syndrome: Acute Kidney Injury-Associated HRS, Rapidly Progressive Renal Failure
- 2 By Type 2 Hepatorenal Syndrome: Chronic Kidney Dysfunction-Associated HRS, Slowly Progressive Renal Failure
- 3 By Other Types: HRS With Cirrhosis, HRS With Acute Liver Failure, HRS With Alcoholic Hepatitis

### Highlights of the Regional Insights of the Hepatorenal Syndrome Market:

North America held the reins of market leadership in 2024. However, the Asia-Pacific region is expected to chart the fastest growth trajectory in the forecast period. Other regions dissected in the hepatorenal syndrome market report are Western Europe, Eastern Europe, South America, the Middle East, and Africa.

### Browse Through More Similar Reports By The Business Research Company:

Hepatorenal Syndrome Treatment Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/hepatorenal-syndrome-treatment-global-market-report>

Rare Kidney Diseases Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report>

Kidney Dialysis Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/kidney-dialysis-global-market-report>

The Business Research Company has built a reputation for delivering comprehensive, data-rich research insights across 27 industries spanning 60+ geographies. With a cache of 1,500,000 datasets, insightful secondary research, and unique insights from industry leaders, The Business Research Company ensures unparalleled information services to remain ahead of the curve.

Contact us at

The Business Research Company: <https://www.thebusinessresearchcompany.com/>

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [info@tbrc.info](mailto:info@tbrc.info)

Nurturing professional alliances on:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

YouTube: [https://www.youtube.com/channel/UC24\\_fI0rV8cR5DxICpgmyFQ](https://www.youtube.com/channel/UC24_fI0rV8cR5DxICpgmyFQ)

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

[info@tbrc.info](mailto:info@tbrc.info)

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/812246615>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.